S_ary Recent data have shown that the in vitro and in vivo cytotoxicity of bioreductive drugs could be significantly increased when combined with chemotherapy drugs such as cisplatinum, depending on the timing of administration. The aim of this study was to define the toxicity (animal lethaity) and the activity (growth delay assay, excision assay) of a bioreductive drug, tirapazamine, alone and combined with chemotherapy agents (5-FU, VP16, bleo, DTIC and c-DDP) on nude mice bearing xenografted human tumours: a rectal carcinoma (HRT18) and a melanoma (Nal I +). Animal lethality was markedly increased when tirapazamine at the lethal dose 10% was combined with the other drugs. For the HRT18 tumour the combination of tirapazamine and bleomycin significantly increased the delay of regrowth compared with bleomycin alone (P=0.04) and was more cytotoxic than tirapazamine alone (P=0.04). For the Nall+ tumours the combination of tirapazamine with VP16 significantly increased tumour doubling time compared with the controls (P=0.001) or VP16 alone. The combination of tirapazamine and VP16 was more cytotoxic than VP16 alone (P=0.0001). When compared with c-DDP or tirapazamine alone, there was a significant decrease in plating efficiency when tirapazamine and c-DDP were given at the same time (P=0.04), but not when tirapazamine was given 3 h before c-DDP. In conclusion, tirapazamine was shown to be cytotoxic against clonogenic human tumour cells. Its efficacy in vivo may depend on its combination with already active chemotherapy drugs on the tumour model used. The timing of administration may be less important than previously thought.
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Keywords human tumour cell lines; tirapazamine; chemotherapy drugs; growth delay assay; excision assay One of the main problems in the treatment of cancer is to define therapeutic approaches specifically directed against tumour cells, and which are non-toxic for normal cells. Rodent and xenografted human tumours contain hypoxic cells which are radioresistant (Rockwell and Moulder 1990; Guichard, 1989) and/or resistant to some cytotoxic drugs, such as alkylating agents (Teicher et al., 1981; Sakata et al., 1991) . In patients, tumour tissues are less well oxygenated than normal tissues (Vaupel, 1990; Lartigau et al., 1993; and hypoxic tumour cells could be a specific target for various treatment modalities (Coleman, 1988) .
There have been efforts over the last 30 years to overcome radioresistance due to cellular hypoxia (Overgaard, 1991) . Concerning the chemoresistance due to hypoxia, most of the studies have looked at the variations in efficacy of drugs when exposed to air or severe hypoxia (Teicher et al., 1981) . More recently, studies have focused on the cytotoxicity of drugs at various oxygen tensions (Po2). Of particular interest are the bioreductive drugs, which are activated under hypoxic conditions to form cytotoxic metabolites (Workman and Stratford, 1993) . To be active against tumour cells and nontoxic to normal cells, these drugs must be metabolised at the low Po2 levels most often present in the tumours, i.e. around 0.2% of oxygen or 1.5 mmHg (Vaupel, 1990; Lartigau et al., 1993) .
The bioreductive drug tirapazamine (SR4233, WIN 59075) has been investigated in vitro and in vivo for its cytotoxic and/or radiosensitising activity against tumour cells in air and in hypoxia (Zeman et al., 1986 (Zeman et al., , 1988 (Zeman et al., , 1990 Brown, 1993; Koch, 1993) . A higher aerobic-hypoxic ratio (concentration in air -concentration in nitrogen to obtain the same cytotoxicity) have been found in murine than in human tumours (Zeman et al., 1986) . More recent data on murine tumours have shown that the cytotoxicity of tirapazamine in vitro and in vivo is significantly increased when combined with other chemotherapy drugs such as cisplatinum, a frequently used drug in the treatment of malignancies (mainly embryonal tumours and squamous carcinoma) (Holden et al., 1992; Dorie and Brown, 1993) . With this last drug, highly significant cell toxicity was demonstrated in a murine tumour, RIF-1, together with dose and time dependence. The maximal response was observed when tirapazamine was given 2-3 h before c-DDP (Dorie and Brown, 1993) . Furthermore, tirapazamine did not enhance the kidney damages resulting from c-DDP (Dorie and Brown, 1993) .
Other drugs are routinely used in clinical practice, such as 5-fluorouracil (5-FU), bleomycin (bleo), etoposide (VP16) and dacarbazine (DTIC). These drugs are given alone or in combination and according to tumour type. Thus for example, DTIC is the reference chemotherapy agent in advanced melanoma. Furthermore, the activity of these drugs varies according to Po2. Bleo and DTIC are preferentially toxic to aerobic cells and 5-FU and c-DDP have no selective toxicity based on cellular oxygenation (Teicher et al., 1981) . To our knowledge no data are available for VP16. To increase tumour cell toxicity, it could be useful to combine drugs activated under hypoxia and drugs toxic against aerobic cells or without any oxygen-dependent activity.
We decided to test the in vivo effects of tirapazamine alone and combined with other chemotherapy agents on two human cell lines: a rectal adenocarcinoma (HRT18) and a melanoma (Nal 1 + ). The choice of the chemotherapy agents was based on their known activity in human models. Different assays were used (animal lethality, growth delay assay, excision assay) for tirapazamine given alone or combined with the various agents (5-FU, VP16, bleo, DTIC and c-DDP) on nude mice bearing the two xenografted human tumours. (Steel and Peckham 1992) . All surviving animals were sacrificed at 3 months.
Materials and methods
Growth delay assay This assay was performed for animals treated by tirapazamine, bleo, 5-FU, VP16 and DTIC given alone or combined. The tumours were measured two or three times a week (three orthogonal diameters) using a vernier caliper. Tumour volumes were calculated using the formula of a hemiellipsoid, the geometric figure most nearly approximating the shape of the tumours. At the time of treatment, the tumour volumes ranged from 75 to 225 mm3. The growth delay assay was determined by measuring the time taken for the tumour to double in volume from the first day of drug injections. The specific growth delay was calculated according to the Steel and Peckham (1992) 
Excision assay
The efficacy of the drug giving the longest growth delay in combination with tirazapamine (4 day schedule) was tested with an in vivo-in vitro colony assay, i.e. bleo for HRT18 and VP16 for Nal1 +. The mice were killed 24 h after the last drug injection and the tumours were excised, minced and dissociated with an enzyme cocktail. The cell suspension was filtered and the cells plated for clonogenic assay. After 2 weeks of incubation (37°C, 5% carbon dioxide humidified atmosphere), the colonies were fixed, stained with a solution of crystal violet and counted.
c Tumour doubling time and specific growth delas' (Table III) HRT18 Treatment with tirazapamine, VP16 or 5-FU alone did not delay tumour regrowth. Only bleo alone significantly delayed tumour regrowth (P=0.001). Tumour growth was constant for HRT18. The combination of tirapazamine and bleomycin significantly increased the delay of regrowth compared with that produced by bleomycin or tirapazamine alone (P=0.04) (Figure 1 ). The regrowth delay produced (Tables IV and V) For HRT18, the cell yield was significantly decreased with the combination of tirapazamine and bleo compared with the control group (P=0.015) (Table IV) . However, an increase in cell yield was observed when tirapazamine was injected 3 h before bleo compared with simultaneous injection. The plating efficiency was significantly decreased with bleo alone (P=0.001), tirapazamine and bleo (P=0.0001) and tirapazamine 3h before bleo (P=0.001) compared with the control group. The combination of tirapazamine and bleomycine was more cytotoxic than tirapazamine alone (P= 0.04), but not different from bleomycine alone (P= 0.06). There was no difference between tirapazamine given 3 h or immediately before bleomycin. The lowest relative clonogenicity was observed with the combination of tirapazamine and bleo given at the same time (0.12). The effect of the combination of tirapazamine and c-DDP was comparable with tirapazamine alone, and did not differ from the control group.
For the Nall+ cell line, there was no significant modification of the cell yield with VP16 and tirapazamine (Table IV) . A significant decrease in plating efficiency was observed with tirapazamine alone (P=0.002), and tirapmine and VP16 (P=0.0001). Tirapazanine was more effective than VP16 (P=0.005), and the combination of tirapazamine and VP16 was more effective than VP16 alone (P=0.0001). There was no difference between tirapazaiine given 3 h or immediately before VP16. The lowest relative clonogenicity was observed with the combination of tirapazamine and VP16 given at the same time (0.21). With c-DDP, no differences were detected for the cell yield in treated animals with the controls (Table V) . There was a significant decrease in plating efficiency when tirapazamine and c-DDP were given at the same time (P= 0.04), compared with c-DDP or tirapazamine alone. This effect was not significant with a 3 h interval between the injections.
Diacssion
In patients, polarographic studies have shown large differences in oxygenation between normal tissues and tumours (Vaupel, 1990; Lartigau et al., 1993) . In tumours Vaupel, 1990; Lartigau et al., 1993; H6ckel et al., 1993) . Very low Po, values can represent more than 25% of the recorded values in metastatic neck nodes (Lartigau et al., 1993) , but are very uncommon in normal tissues (Vaupel, 1990; Lartigau et al., 1993 Lartigau et al., , 1994 (Bremmer, 1990; Koch, 1993; Brown, 1993; Workman and Stratford, 1993) . One of the bioreductive drugs currently being tested in phase I in man (Doherty et al., 1994 ) is tirapazamine (SR-4233). Tirapazamine has a lower hypoxic cytotoxic ratio in human cell lines (between 15 and 50) than in murine cell lines (Zeman et al., 1986) , and it has recently been shown that tirapazam ne toxicity extends over a large range of oxygen concentrations (Costa et al., 1989; Koch, 1993; Lartigau and Guichard, 1995) . To improve tumour control, the combination of radiotherapy and chemotherapy is currently strongly advocated (Schilsky, 1992; Rockwell, 1992) . The bioreductive drugs could be associated to agents more cytotoxic in air than in hypoxia (bleo, procarbazine, vincristine), or to agents without any selective cytotoxicity according to tissue oxygenation (5-FU, c-DDP) (Teicher et al., 1981) . Before clinical implementation, such combinations have first to be tested in relevant experimental models.
Concerning mouse lethality, a 10% lethality with tirapazamine alone was obtained for a total injected dose of around 500 mg m-2, corresponding to four successive daily injections of 0.20 mmol kg-' or 36 mg kg-'. These results are similar to those obtained by others with rodent tumours (Zeman et al., 1986; Minchinton et al., 1992; Spiegel et al., 1993) . However, it must be emphasised that, in this study, the combination of tirapazamine and other chemotherapy agent always increased mice lethality. It (Minchinton et al., 1992 ; SF Chen, personal communication). For a human colon cell line (HT29), tirapazamine or c-DDP had only marginal anti-tumour effect in an in vivo tumour growth delay assay (SF Chen, personal communication). For Nail +, a modification in tumour growth was noticed with delayed cytotoxicity. However, for this cell line the calculated volume doubling time and specific growth delay did not reflect precisely the biological effect of the drugs. The biological effect was in fact larger than that appreciated only with the calculation of the tumour doubling time. The late decrease in tumour volume, noticed at day 30 only, may have depended on the time necessary for this anoxic tumour to eliminate the dead cells.
For the excision assay, some effects on plating efficiency were noticed with the combination of drugs found to be the most active in the growth delay assay: tirapazamme and bleo for HRT18 and tirapazamine and VP16 for Nall +. However, the effect of these drugs were not as marked as those previously published by Holden or Dorie, who showed a very marked increase in toxicity when tirapazamine was injected 3 h before c-DDP (Holden et al., 1992; Dorie and Brown, 1993) . In particular, the timing of administration was not crucial in our experiments and the administration of tirapazamine 3 h before the other drug did not increase significantly tumour cell kill. We have no explanation for these differences. However, it must be emphasised that variations in experimental results can be found when using different tumour models, as for example between human and murine cell lines (Guichard, 1989) . For the combination of tirapazamine and c-DDP a marked increase in plating efficiency was noted for HRT18, with the opposite effect for Na 11 +. We have no explanation for such a result, but we feel that it should lead to more caution about using such a combination in patients.
In conclusion, tirapazamine was shown to be cytotoxic in vivo against clonogenic tumour cells. This efficacy may depend on the combination of tirapazamine with already active chemotherapy drugs on the tumour model studied (bleo on HRT18 and VP16 on Nal 1 + ). Some late effect on tumour growth was found in one of our xenografted tumours (Nal 1 + ), this not being precisely demonstrated by the calculation of the volume doubling time. Thus, the model used is very important to describe precisely the biological effect observed. Finally, the timing of drug administration and combination could be less important than previously thought (Dorie and Brown, 1993 
